Analyses of clinical samples, cell lines, patient‐derived organoids, and xenograft models reveal that PRMT1 promotes tumor growth and CBP resistance through a novel, methyltransferase‐independent mechanism. This evidence concerns the gene PRMT1 and neoplasm.